European Medicines Agency’s panel recommends expanding Amgen’s Uplizna to treat IgG4-related disease, with trial data showing reduced flares and higher remission rates.
European Medicines Agency’s panel recommends expanding Amgen’s Uplizna to treat IgG4-related disease, with trial data showing reduced flares and higher remission rates.
Copyright © Louis Velazquez. All Rights Reserved.